Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Policy On Financial Conflicts Of Public Speakers At Advisory Panels Unchanged

This article was originally published in The Pink Sheet Daily

Executive Summary

In final guidance, the agency has rejected calls by the advocacy group Public Citizen to allow committee members to question open public hearing speakers on their finances.

You may also be interested in...



Avandia Meeting Spurs New Scrutiny Of FDA Conflict-Of-Interest Screening

Revelations about speaking and consulting agreements between two FDA advisory committee members, Avandia maker GlaxoSmithKline and Actos maker Takeda, suggest the agency may need to further refine its conflict-of-interest screening procedures to ensure a public perception that it is receiving independent advice from outside experts

Avandia Day Two Might Be Same Old Song Even With Broken RECORD

There may be more at stake for FDA, and the pharmaceutical industry in general, in how the advisory committees interpret the RECORD trial than there is for Avandia itself.

Open Public Hearing Speakers Should Disclose Financial Conflict – Comments

FDA should permit advisory committee members and voting consultants to question open public hearing speakers about their potential conflicts of interest during advisory committee meetings, according to the consumer advocacy group Public Citizen

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071595

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel